Loading news...
Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company's stock after selling 2,975,000 shares during the period.
Microsoft filed on Tuesday a proposed brief in support of Anthropic's lawsuit asking the court to temporarily block the U.S. Department of Defense's designation of the AI startup as a supply-chain risk.
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Granite Investment Partners LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,118,696 shares of the biopharmaceutical company's stock after selling 42,506 shares during the period. Amicus
Guru Stock PicksGeorge Soros has made the following transactions:Reduce in SPSB by 5.19%Sold out in MMYTAdd in AAMI by 61.3%New position in COINStock News Blue
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases, today announced financial results for the full year ended December 31, 2025.
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease and POMBILITI® + OPFOLDA® (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease.
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
Amicus Therapeutics, Inc. (NASDAQ: FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of the company's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the completion of the transaction, the chief executive officer owned 1,021,180 shares in
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus shareholders. Halper Sadeh encourages Amicus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Amicu.
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed lower at the open, but as President Trump addressed the audience at the World Economic Forum in Davos, Switzerland, the moment he mentioned... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More.
Amicus stock soars 135.8% in six months as demand for marketed products grows. The company is set to be acquired by BioMarin for $4.8 billion.
Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum.
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower on Friday, with the venerable S&P 500 taking early bows as it hit a fresh all-time high, joining the Dow Jones Industrial Average... Here Are Monday's Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Amicus will receive $14.50 in cash for each share of Amicus that they own. KSF is seeking to determine whether this consideration and the process.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws